| http://dbpedia.org/ontology/abstract
|
Onyx Pharmaceuticals Inc. has been a bioph … Onyx Pharmaceuticals Inc. has been a biopharmaceutical company headquartered in South San Francisco, California. The company developed and marketed medicines for the treatment of cancer. Onyx was founded in 1992 by Kevin J. Kinsella and Frank McCormick Ph.D., FRS. McCormick served as the chief scientific officer until 1998, while Kinsella was the firm's chairman. In 2009, the company acquired Proteolix, Inc., a private biotechnology company, for $276 million in cash plus additional milestone payments. In January 2012, the company was named "the top biotechnology takeover target in 2012" through an industry survey. Onyx president and chief executive officer (CEO) Tony Coles had said that Onyx liked its prospects as an independent company and was focused on bringing new therapies to patients. However, at the end of August 2013, Amgen announced it was acquiring Onyx in an agreed $10.4 billion deal. Initial funding for the formation of Onyx came from biotechnology firm Chiron Corporation (granted a 43% stake in the new company) and venture capital investors: Avalon Ventures, Institutional Venture Partners, J. H. Whitney & Company, and Kleiner Perkins Caufield & Byers. McCormick had been working on cancer treatments at Chiron before he was selected as vice president of research at the newly formed company, leading the company's research program. The acting president of the firm at its inception was Samuel D. Colella, a partner at Institutional Venture Partners (an original Onyx backer).enture Partners (an original Onyx backer).
|
| http://dbpedia.org/ontology/foundingYear
|
1992
|
| http://dbpedia.org/ontology/industry
|
http://dbpedia.org/resource/Biotechnology +
|
| http://dbpedia.org/ontology/location
|
http://dbpedia.org/resource/South_San_Francisco +
|
| http://dbpedia.org/ontology/numberOfEmployees
|
500
|
| http://dbpedia.org/ontology/parentCompany
|
http://dbpedia.org/resource/Amgen +
|
| http://dbpedia.org/ontology/product
|
http://dbpedia.org/resource/Sorafenib +
|
| http://dbpedia.org/ontology/type
|
http://dbpedia.org/resource/Subsidiary +
|
| http://dbpedia.org/ontology/wikiPageExternalLink
|
http://www.amgen.com +
, http://www.onyxtrials.com/ +
, http://www.onyx-pharm.com/ +
, http://www.nexavar.com/ +
|
| http://dbpedia.org/ontology/wikiPageID
|
33293566
|
| http://dbpedia.org/ontology/wikiPageLength
|
12240
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1074878091
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Category:Companies_formerly_listed_on_the_Nasdaq +
, http://dbpedia.org/resource/Sorafenib +
, http://dbpedia.org/resource/South_San_Francisco +
, http://dbpedia.org/resource/Breast_cancer +
, http://dbpedia.org/resource/Amgen_Inc +
, http://dbpedia.org/resource/Renal_cell_carcinoma +
, http://dbpedia.org/resource/Regorafenib +
, http://dbpedia.org/resource/Hepatocellular_carcinoma +
, http://dbpedia.org/resource/Chief_executive_officer +
, http://dbpedia.org/resource/Category:Life_sciences_industry +
, http://dbpedia.org/resource/Kleiner_Perkins_Caufield_&_Byers +
, http://dbpedia.org/resource/Carfilzomib +
, http://dbpedia.org/resource/California +
, http://dbpedia.org/resource/Category:Orphan_drug_companies +
, http://dbpedia.org/resource/Capecitabine +
, http://dbpedia.org/resource/Subsidiary +
, http://dbpedia.org/resource/Chiron_Corporation +
, http://dbpedia.org/resource/President_%28corporate_title%29 +
, http://dbpedia.org/resource/Amgen +
, http://dbpedia.org/resource/Wikt:inoperable +
, http://dbpedia.org/resource/Colorectal_cancer +
, http://dbpedia.org/resource/Institutional_Venture_Partners +
, http://dbpedia.org/resource/Biotechnology +
, http://dbpedia.org/resource/Biopharmaceutical +
, http://dbpedia.org/resource/Bayer +
, http://dbpedia.org/resource/Chairman +
, http://dbpedia.org/resource/United_States +
, http://dbpedia.org/resource/Category:American_companies_established_in_1992 +
, http://dbpedia.org/resource/Category:Companies_based_in_San_Francisco +
, http://dbpedia.org/resource/Category:Pharmaceutical_companies_established_in_1992 +
, http://dbpedia.org/resource/Avalon_Ventures +
, http://dbpedia.org/resource/J._H._Whitney_&_Company +
, http://dbpedia.org/resource/Proteolix%2C_Inc. +
, http://dbpedia.org/resource/Thyroid_cancer +
, http://dbpedia.org/resource/Category:1992_establishments_in_California +
, http://dbpedia.org/resource/Chief_scientific_officer +
|
| http://dbpedia.org/property/foundation
|
1992
|
| http://dbpedia.org/property/homepage
|
http://www.amgen.com +
|
| http://dbpedia.org/property/industry
|
http://dbpedia.org/resource/Biotechnology +
|
| http://dbpedia.org/property/keyPeople
|
N. Anthony Coles
|
| http://dbpedia.org/property/location
|
http://dbpedia.org/resource/South_San_Francisco +
, http://dbpedia.org/resource/California +
, http://dbpedia.org/resource/United_States +
|
| http://dbpedia.org/property/name
|
Onyx Pharmaceuticals Incorporated
|
| http://dbpedia.org/property/numEmployees
|
500
|
| http://dbpedia.org/property/parent
|
http://dbpedia.org/resource/Amgen +
|
| http://dbpedia.org/property/products
|
http://dbpedia.org/resource/Sorafenib +
|
| http://dbpedia.org/property/type
|
http://dbpedia.org/resource/Subsidiary +
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Use_mdy_dates +
, http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Better_source_needed +
, http://dbpedia.org/resource/Template:Infobox_company +
, http://dbpedia.org/resource/Template:Cite_web +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Pharmaceutical_companies_established_in_1992 +
, http://dbpedia.org/resource/Category:1992_establishments_in_California +
, http://dbpedia.org/resource/Category:American_companies_established_in_1992 +
, http://dbpedia.org/resource/Category:Companies_formerly_listed_on_the_Nasdaq +
, http://dbpedia.org/resource/Category:Life_sciences_industry +
, http://dbpedia.org/resource/Category:Companies_based_in_San_Francisco +
, http://dbpedia.org/resource/Category:Orphan_drug_companies +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Onyx_Pharmaceuticals?oldid=1074878091&ns=0 +
|
| http://xmlns.com/foaf/0.1/homepage
|
http://www.amgen.com +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Onyx_Pharmaceuticals +
|
| http://xmlns.com/foaf/0.1/name
|
Onyx Pharmaceuticals Incorporated
|
| owl:sameAs |
http://rdf.freebase.com/ns/m.03p2whj +
, http://dbpedia.org/resource/Onyx_Pharmaceuticals +
, http://www.wikidata.org/entity/Q7095196 +
, http://yago-knowledge.org/resource/Onyx_Pharmaceuticals +
, https://global.dbpedia.org/id/4sqgH +
|
| rdf:type |
http://dbpedia.org/class/yago/WikicatCompaniesBasedInSanFrancisco%2CCalifornia +
, http://dbpedia.org/class/yago/SocialGroup107950920 +
, http://dbpedia.org/class/yago/Institution108053576 +
, http://dbpedia.org/class/yago/YagoLegalActorGeo +
, http://dbpedia.org/class/yago/YagoLegalActor +
, http://dbpedia.org/ontology/Agent +
, http://dbpedia.org/class/yago/Company108058098 +
, http://dbpedia.org/class/yago/Organization108008335 +
, http://dbpedia.org/class/yago/Group100031264 +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#SocialPerson +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#Agent +
, http://schema.org/Organization +
, http://www.wikidata.org/entity/Q4830453 +
, http://www.wikidata.org/entity/Q43229 +
, http://dbpedia.org/class/yago/Abstraction100002137 +
, http://dbpedia.org/class/yago/WikicatBiotechnologyCompaniesOfTheUnitedStates +
, http://dbpedia.org/class/yago/YagoPermanentlyLocatedEntity +
, http://dbpedia.org/ontology/Organisation +
, http://dbpedia.org/ontology/Company +
, http://www.wikidata.org/entity/Q24229398 +
|
| rdfs:comment |
Onyx Pharmaceuticals Inc. has been a bioph … Onyx Pharmaceuticals Inc. has been a biopharmaceutical company headquartered in South San Francisco, California. The company developed and marketed medicines for the treatment of cancer. Onyx was founded in 1992 by Kevin J. Kinsella and Frank McCormick Ph.D., FRS. McCormick served as the chief scientific officer until 1998, while Kinsella was the firm's chairman. In 2009, the company acquired Proteolix, Inc., a private biotechnology company, for $276 million in cash plus additional milestone payments. In January 2012, the company was named "the top biotechnology takeover target in 2012" through an industry survey. Onyx president and chief executive officer (CEO) Tony Coles had said that Onyx liked its prospects as an independent company and was focused on bringing new therapies to patientcused on bringing new therapies to patient
|
| rdfs:label |
Onyx Pharmaceuticals
|
